HK1203952A1 - 取代的苯並噻吩基-吡咯並三嗪及其在癌症治療中的用途 - Google Patents
取代的苯並噻吩基-吡咯並三嗪及其在癌症治療中的用途Info
- Publication number
- HK1203952A1 HK1203952A1 HK15104558.9A HK15104558A HK1203952A1 HK 1203952 A1 HK1203952 A1 HK 1203952A1 HK 15104558 A HK15104558 A HK 15104558A HK 1203952 A1 HK1203952 A1 HK 1203952A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pyrrolotriazines
- treatment cancer
- substituted benzothienyl
- benzothienyl
- substituted
- Prior art date
Links
- SSTMBTQFNVRJDU-UHFFFAOYSA-N C1=CC=C2SC(C=3N=NNC4=CC=NC4=3)=CC2=C1 Chemical class C1=CC=C2SC(C=3N=NNC4=CC=NC4=3)=CC2=C1 SSTMBTQFNVRJDU-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11193839 | 2011-12-15 | ||
| PCT/EP2012/075127 WO2013087647A1 (en) | 2011-12-15 | 2012-12-11 | Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1203952A1 true HK1203952A1 (zh) | 2015-11-06 |
Family
ID=47501132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15104558.9A HK1203952A1 (zh) | 2011-12-15 | 2015-05-14 | 取代的苯並噻吩基-吡咯並三嗪及其在癌症治療中的用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9598416B2 (zh) |
| EP (1) | EP2791143B1 (zh) |
| JP (1) | JP6047582B2 (zh) |
| CN (1) | CN104159900B (zh) |
| CA (1) | CA2862981C (zh) |
| ES (1) | ES2570862T3 (zh) |
| HK (1) | HK1203952A1 (zh) |
| WO (1) | WO2013087647A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI753892B (zh) | 2016-03-28 | 2022-02-01 | 美商英塞特公司 | 作為ｔａｍ抑制劑之吡咯并三嗪化合物 |
| AU2017355603A1 (en) | 2016-11-04 | 2019-06-20 | Auckland Uniservices Limited | Tricyclic heterocyclic derivatives and uses thereof |
| AU2018317153B2 (en) * | 2017-08-15 | 2021-12-23 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | FGFR inhibitor and medical application thereof |
| MX2020004285A (es) * | 2017-10-25 | 2020-07-29 | Bayer Pharma AG | Proceso para preparar el benzotiofen-2-il boronato. |
| US20220177475A1 (en) * | 2019-02-15 | 2022-06-09 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Fgfr inhibitor compound in solid form and preparation method therefor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997025033A1 (en) | 1995-10-31 | 1997-07-17 | Eli Lilly And Company | Antithrombotic diamines |
| WO2000071129A1 (en) | 1999-05-21 | 2000-11-30 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| MXPA02002938A (es) | 1999-09-17 | 2004-12-06 | Abbott Gmbh & Co Kg | Inhibidores de cinasa como agentes agentes terapeuticos. |
| AU2004282219C1 (en) * | 2003-10-15 | 2009-12-17 | Osi Pharmaceuticals, Inc. | Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors |
| PT1740591E (pt) | 2004-04-02 | 2009-09-24 | Osi Pharm Inc | Inibidores da proteína quinase heterobicíclicos em substituição de anel bicíclico 6,6 |
| UY28931A1 (es) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| WO2007056170A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| SI1951724T1 (sl) | 2005-11-17 | 2011-09-30 | Osi Pharmaceuticals Llc | Kondenzirani biciklični mTOR inhibitorji |
| US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
| EP1957485B1 (en) | 2005-12-02 | 2013-02-13 | Bayer HealthCare, LLC | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| JP5193876B2 (ja) | 2005-12-02 | 2013-05-08 | バイエル・ヘルスケア・エルエルシー | オーロラキナーゼの阻害により癌を処置するために有用なピロロトリアジン誘導体 |
| US7772231B2 (en) | 2005-12-29 | 2010-08-10 | Abbott Laboratories | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors |
| US8124759B2 (en) | 2007-05-09 | 2012-02-28 | Abbott Laboratories | Inhibitors of protein kinases |
| US8138336B2 (en) * | 2007-09-25 | 2012-03-20 | Bayer Healthcare Llc | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| JP5656976B2 (ja) | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | ピロロトリアジン化合物 |
-
2012
- 2012-12-11 WO PCT/EP2012/075127 patent/WO2013087647A1/en active Application Filing
- 2012-12-11 JP JP2014546466A patent/JP6047582B2/ja not_active Expired - Fee Related
- 2012-12-11 ES ES12809680T patent/ES2570862T3/es active Active
- 2012-12-11 CA CA2862981A patent/CA2862981C/en active Active
- 2012-12-11 EP EP12809680.7A patent/EP2791143B1/en active Active
- 2012-12-11 CN CN201280061635.1A patent/CN104159900B/zh active Active
- 2012-12-11 US US14/365,024 patent/US9598416B2/en active Active
-
2015
- 2015-05-14 HK HK15104558.9A patent/HK1203952A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN104159900B (zh) | 2016-08-24 |
| JP6047582B2 (ja) | 2016-12-21 |
| US20150080371A1 (en) | 2015-03-19 |
| WO2013087647A1 (en) | 2013-06-20 |
| CN104159900A (zh) | 2014-11-19 |
| CA2862981A1 (en) | 2013-06-20 |
| EP2791143B1 (en) | 2016-02-24 |
| US9598416B2 (en) | 2017-03-21 |
| JP2015500315A (ja) | 2015-01-05 |
| EP2791143A1 (en) | 2014-10-22 |
| ES2570862T3 (es) | 2016-05-20 |
| CA2862981C (en) | 2020-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201207574B (en) | Phytocannabinoids in the treatment of cancer | |
| IL233051A0 (en) | Anti-phf-tau antibodies and uses thereof | |
| EP2751270A4 (en) | OLIGOMER CONJUGATE COMPLEXES AND ITS USE | |
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| ZA201307302B (en) | Cd37-binding molecules and immunoconjugates thereof | |
| GB201120993D0 (en) | Novel compounds and their use in therapy | |
| EP2701730A4 (en) | MFG-E8 AND USES THEREOF | |
| EP2817304A4 (en) | NOVEL COMPOUNDS AND THEIR THERAPEUTIC USE | |
| HK1203952A1 (zh) | 取代的苯並噻吩基-吡咯並三嗪及其在癌症治療中的用途 | |
| EP2716359A4 (en) | COMPLEX AND USES THEREOF | |
| SI2872176T1 (sl) | Karboranilporfirin za uporabo pri zdravljenju raka | |
| HK1203430A1 (zh) | 可用於治療炎症和癌症的二芳基磺酰胺 | |
| EP2744786A4 (en) | SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER | |
| IL237400B (en) | Rhizobacteria and its uses | |
| GB201718726D0 (en) | Phytocannabinoids in the treatment of cancer | |
| EP2693879A4 (en) | MIGRASTATINES AND THEIR USES | |
| EP2717900A4 (en) | SCAFFOLD KINASE INTERACTION BLOCKADES AND ITS USE IN CANCER TREATMENT | |
| HUP1000688A2 (en) | Use of trifluoro-phthalimides in the treatment of cancer | |
| AU2012266896A1 (en) | Scaffold-kinase interaction blockades and uses thereof in treating cancer | |
| GB201117876D0 (en) | Peptides and their use in treatment | |
| GB201102208D0 (en) | Inventions and therapy | |
| GB201102228D0 (en) | Inventions and therapy | |
| GB201102212D0 (en) | Inventions and therapy | |
| GB201102221D0 (en) | Inventions and therapy | |
| GB201102222D0 (en) | Inventions and therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20231208 |